TriangleHEALTH PROFESSIONAL · SOURCE READING
Hematopoietic stem cell transplant (HSCT)
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
HSCT has been used in patients with multisystem high–risk-organ involvement that is refractory to chemotherapy.[142,154-157] Early results showing very high treatment-related mortality in these ill young infants led to the development of reduced-intensity conditioning.
Evidence (reduced-intensity conditioning vs. myeloablative conditioning for HSCT):
A review from the United Kingdom suggested that in transplant centers that have LCH HSCT experience, there was no advantage to reduced-intensity conditioning in their setting.[158][Level of evidence C2]
Source links and citations
A review from the United Kingdom suggested that in transplant centers that have LCH HSCT experience, there was no advantage to reduced-intensity conditioning in their setting.[158][Level of evidence C2]
Reduced-intensity conditioning provided no OS advantage over myeloablative conditioning for LCH patients; the relapse rate after reduced-intensity conditioning was significantly higher (28%) than the relapse rate after myeloablative conditioning (8%).
A review from the United Kingdom suggested that in transplant centers that have LCH HSCT experience, there was no advantage to reduced-intensity conditioning in their setting.[158][Level of evidence C2]
Many of the patients who received reduced-intensity conditioning and relapsed were successfully re-treated with chemotherapy alone.
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice